Technologies Announces Receipt of Complete Response Letter From FDA

Technologies Announces Receipt of Complete Response Letter From FDA

Citing Issues at the Facility

of the Supplier of the Active Ingredient

LYON, FRANCE - April 29, 2014

- Flamel Technologies (NASDAQ: FLML) today announced today that it has received a complete response letter (CRL) from the

U.S. Food and Drug Administration (FDA) for its second New Drug Application (NDA) application from the clat portfolio.

A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the NDA

in its current form.

In the CRL, the FDA noted that during a

recent inspection of the manufacturing facility of the active pharmaceutical ingredient's (API) supplier, deficiencies were

found. Satisfactory resolution of these facility deficiencies is required before this application may be approved. There were no

other deficiencies in the CRL. Final agreement on the draft product labeling is also pending.

"While we are disappointed by this

delay, we believe that our application is sound and will work with the API supplier to resolve any open issues. We will do everything

in our power to submit the information sought by the FDA in order for them to reconsider our NDA as soon as possible," said

Michael S. Anderson, President and Chief Executive Officer. "Since the CRL was received late yesterday on our PDUFA date,

we do not feel it is prudent to provide an estimate of the timing of the resubmission of the NDA, or the timeline for eventual

FDA action on that resubmission. We will communicate any update on the status of this second NDA to our investors when appropriate."

About Flamel Technologies. Flamel

Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery

capabilities. The company markets Bloxiverz (neostigmine methylsulfate) in the USA and manufactures Micropump-based microparticles

under FDA-audited GMP guidelines for Coreg CR (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company

has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal

of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes biological and

chemical drugs formulated with its Medusa and Micropump (and its applications to the development of liquid formulations,

i.e. LiquiTime and of abuse-deterrent formulations Trigger Lock ) proprietary drug delivery platforms. Several Medusa-based

products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St.

Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com.

This release contains "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations,

goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly

historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect,"

"estimate," "plan," "will," "may," and similar expressions are generally intended to identify

forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond

our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These

risks include risks that the launch of Bloxiverz will not be as successful as anticipated; our ability to bring other R&D projects

of the former clat Pharmaceuticals to market may be unsuccessful; FDA may not take action on the status of unapproved versions

of neostigmine still on the market; clinical trial results may not be positive or our partners may decide not to move forward;

products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements;

products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities;

we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology;

and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described

more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2012 that has been filed with the Securities

and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the

time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information,

future events or otherwise.